share_log

Benchmark Reiterates Buy on Emergent BioSolutions, Maintains $5 Price Target

Moomoo 24/7 ·  Apr 11 09:05

Benchmark analyst Robert Wasserman reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment